

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Societe des Produits Nestle S.A.</u> <hr/> (Last) (First) (Middle) <u>AVENUE NESTLE 55</u> <hr/> (Street) <u>CH-1800, VEVEY V8</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Aimmune Therapeutics, Inc. [AIMT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/07/2020</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/07/2020		P		1,000,000	A	\$31.97	12,727,113 ⁽¹⁾	I	See Footnote ⁽¹⁾
Series A Preferred Stock	02/07/2020		P		525,634	A	\$319.675	525,634 ⁽²⁾	I	See Footnote ⁽²⁾
Common Stock	04/22/2020		J ⁽³⁾		12,727,113	A	\$16.11	12,727,113 ⁽³⁾	I	See Footnote ⁽³⁾
Series A Preferred Stock	04/22/2020		J ⁽³⁾		525,634	A	\$161.1	525,634 ⁽³⁾	I	See Footnote ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Societe des Produits Nestle S.A.

 (Last) (First) (Middle)
AVENUE NESTLE 55

 (Street)
CH-1800, VEVEY V8

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
NESTLE SA

 (Last) (First) (Middle)
AVENUE NESTLE 55

 (Street)
CH-1800, VEVEY V8

 (City) (State) (Zip)

Explanation of Responses:

1. Consists of 12,727,113 shares of Common Stock held by Nestle Health Science US Holdings, Inc. ("NHS"). NHS is a wholly owned subsidiary of NIMCO US, Inc. ("NIMCO"). NIMCO, in turn, is a wholly-owned subsidiary of Nestle US Holdco, Inc. ("Nestle US Holdco"), which is a wholly-owned subsidiary of Societe des Produits Nestle S.A. ("SPN"). The ultimate parent company of NHS, NIMCO, Nestle US Holdco and SPN is Nestle S.A. ("Nestle"). Following the purchase referred to in the table above and prior to the internal transfer referred to in Note 3 below, each of these entities may be deemed to share voting and investment power with respect to all shares of Common Stock held by NHS. Each of NIMCO, Nestle US Holdco, SPN and Nestle disclaims beneficial ownership of such shares of Common Stock except to the extent of its pecuniary interest therein.

2. Consists of 525,634 shares of Series A Preferred Stock held by NHS with each share of Series A Preferred Stock convertible into ten shares of Common Stock. Following the purchase and prior to the internal transfer referred to in Note 3 below, each of NHS, NIMCO, Nestle US Holdco, SPN and Nestle may be deemed to share voting and investment power with respect to these shares of Series A Preferred Stock held by NHS. Each of NIMCO, Nestle US Holdco, SPN and Nestle disclaims beneficial ownership of such shares of Series A Preferred Stock except to the extent of its pecuniary interest therein.

3. This transaction constitutes an internal transfer of 12,727,113 shares of Common Stock and 525,634 shares of Series A Preferred Stock from NHS to SPN. Following the transfer, SPN and Nestle may be deemed to share voting and investment power with respect to all shares of Common Stock and Series A Preferred Stock. Nestle disclaims beneficial ownership of such shares of Common Stock and Series A Preferred Stock except to the extent of its pecuniary interest therein. Subsequent to this internal transfer, each of NHS, NIMCO, and Nestle US Holdco no longer hold any shares of Common Stock or Series A Preferred Stock and are therefore no longer Reporting Owners.

Remarks:

NESTLE HEALTH SCIENCE
US HOLDINGS, INC. By: 04/24/2020
Name: James Pepin, Title:
Director and President
NIMCO US, INC. By: Name:
Dan Nugent, Title: Chief 04/24/2020
Legal Officer and General
Counsel
NESTLE US HOLDCO, INC.
By: Name: Michael Prewitt, 04/24/2020
Title: Secretary
SOCIETE DES PRODUITS
NESTLE S.A. By: Name: 04/24/2020
Claudio Kuoni, Title: Vice
President
NESTLE S.A. By: Name:
Gregory Behar, Title: Deputy 04/24/2020
Executive Vice President
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.